Cat. No.: HY-110177

SP-100030

1 Cited Publications

고객리뷰

Based on 1 publication(s) in Google Scholar

SP-100030 is a potent NF-κB and activator protein-1 (AP-1) double inhibitor (IC₅₀s=50 and 50 nM, respectively). SP-100030 inhibits IL-2, IL-8, and TNF-alpha production in Jurkat and other T cell lines. SP-100030 decreases murine collagen-induced arthritis (CIA).

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.57%
CAS No.: 154563-54-9
화학식: C₁₄H₅ClF₉N₃O
분자량:437.65

보관:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

SP-100030 Chemical Structure

CAS No.: 154563-54-9

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
용액&용해도
- In Vitro
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

All NF-κB Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Jurkat	EC₅₀	550 nM Compound: 6; SP100030	Cytotoxicity against human Jurkat cells incubated for 24 hrs by celltiter glo assay Cytotoxicity against human Jurkat cells incubated for 24 hrs by celltiter glo assay	[PMID: 39005064]
Jurkat	IC₅₀	0.05 μM Compound: 1, SP100030	Inhibition of AP-1-mediated transcriptional activation in human Jurkat cells by luciferase reporter gene assay Inhibition of AP-1-mediated transcriptional activation in human Jurkat cells by luciferase reporter gene assay	[PMID: 24831826]
Jurkat	IC₅₀	0.05 μM Compound: 1, SP100030	Inhibition of NF-kappaB-mediated transcriptional activation in human Jurkat cells by luciferase reporter gene assay Inhibition of NF-kappaB-mediated transcriptional activation in human Jurkat cells by luciferase reporter gene assay	[PMID: 24831826]
Jurkat	IC₅₀	0.05 μM Compound: 1	Concentration required to inhibit activator protein-1(AP-1) mediated transcriptional activation in human Jurkat T-cells Concentration required to inhibit activator protein-1(AP-1) mediated transcriptional activation in human Jurkat T-cells	[PMID: 11052805]
Jurkat	IC₅₀	0.05 μM Compound: 1	Concentration required to inhibit nuclear factor-kappa B) mediated transcriptional activation in human Jurkat T-cells. Concentration required to inhibit nuclear factor-kappa B) mediated transcriptional activation in human Jurkat T-cells.	[PMID: 11052805]
Jurkat	IC₅₀	0.05 μM Compound: 28	In vitro inhibitory activity against human Jurkat T-Cells stably transfected with activating transcription factor 1 In vitro inhibitory activity against human Jurkat T-Cells stably transfected with activating transcription factor 1	[PMID: 9484492]
Jurkat	IC₅₀	0.05 μM Compound: 28	In vitro inhibitory activity against human Jurkat T-Cells stably transfected with an Nuclear factor kappa B transcription factor In vitro inhibitory activity against human Jurkat T-Cells stably transfected with an Nuclear factor kappa B transcription factor	[PMID: 9484492]

In Vitro

SP-100030 blocks the production of IL-2 and IL-8 in Jurkat T-cells at the same concentrations as seen in the luciferase assay (IC₅₀≈30 nM)^[1].
? ELISA and RT-PCR confirmed that IL-2, IL-8, and TNF-alpha production by activated Jurkat and other T cell lines were inhibited by SP100030^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SP100030 (10 mg/kg/day; i.p.; day 21 to day 34) significantly decreased arthritis severity^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Six- to 8-wk-old male DBA/1J mice (immunized with type II collagen)^[2]
Dosage:

10 mg/kg
Administration:

I.p.; daily, starting at day 21 to the end of the study on day 34
Result:

Significantly decreased arthritis scores compared with controls; Histologic evaluation of the paws from mice treated from day 20 to 34 showed a trend toward decreased inflammation.

Chemical Information

CAS No. 154563-54-9
Appearance Solid
분자량 437.65
화학식 C₁₄H₅ClF₉N₃O
Color Off-white to light yellow
SMILES

FC(F)(F)C1=CC(C(F)(F)F)=CC(NC(C2=CN=C(Cl)N=C2C(F)(F)F)=O)=C1
선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Sci Adv

Noncanonical role of Golgi-associated macrophage TAZ in chronic inflammation and tumorigenesis. [Abstract]

2025 Jan 24;11(4):eadq2395. PMID: 39841821

용액&용해도

In Vitro:

DMSO : 50 mg/mL (114.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2849 mL

11.4247 mL

22.8493 mL

5 mM

0.4570 mL

2.2849 mL

4.5699 mL

10 mM

0.2285 mL

1.1425 mL

2.2849 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Sullivan RW, et al. 2-Chloro-4-(trifluoromethyl)pyrimidine-5-N-(3',5'- bis(trifluoromethyl)phenyl)-carboxamide: a potent inhibitor of NF-kappa B- and AP-1-mediated gene expression identified using solution-phase combinatorial chemistry. J Med Chem. 1998;4 [Content Brief]

[2]. Gerlag DM, et al. The effect of a T cell-specific NF-kappa B inhibitor on in vitro cytokine production and collagen-induced arthritis. J Immunol. 2000;165(3):1652-1658. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2849 mL	11.4247 mL	22.8493 mL	57.1233 mL
	5 mM	0.4570 mL	2.2849 mL	4.5699 mL	11.4247 mL
	10 mM	0.2285 mL	1.1425 mL	2.2849 mL	5.7123 mL
	15 mM	0.1523 mL	0.7616 mL	1.5233 mL	3.8082 mL
	20 mM	0.1142 mL	0.5712 mL	1.1425 mL	2.8562 mL
	25 mM	0.0914 mL	0.4570 mL	0.9140 mL	2.2849 mL
	30 mM	0.0762 mL	0.3808 mL	0.7616 mL	1.9041 mL
	40 mM	0.0571 mL	0.2856 mL	0.5712 mL	1.4281 mL
	50 mM	0.0457 mL	0.2285 mL	0.4570 mL	1.1425 mL
	60 mM	0.0381 mL	0.1904 mL	0.3808 mL	0.9521 mL
	80 mM	0.0286 mL	0.1428 mL	0.2856 mL	0.7140 mL
	100 mM	0.0228 mL	0.1142 mL	0.2285 mL	0.5712 mL

Keywords

SP-100030

1 Cited Publications

100 mg 견적 받기

Subscribe to the

MedChemExpress

Newsletter

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

SP-100030

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Chemokine Compound Library

Cancer Stem Cells Compound Library

Coagulation and Anti-coagulation Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) SP-100030

All NF-κB Isoforms

Biological Activity

Chemical Information

Publications (1)

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

SP-100030 Related Classifications

HY-110177 Related Classifications